CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that Phase 2 results for vadadustat in dialysis patients with anemia related to chronic kidney disease (CKD), including new pharmacokinetic data, will be presented in a poster presentation at the National Kidney Foundation 2016 Spring Clinical Meetings taking place in Boston from April 27-May 1.
